论文部分内容阅读
目的探索坎地沙坦和氟桂利嗪在预防性治疗偏头痛中的价值。方法 132例偏头痛患者,随机分成A组和B组,每组66例。A组患者给予坎地沙坦治疗,B组患者给予氟桂利嗪治疗,对比两组患者的头痛发作状况、头痛指数、不良反应发生率。结果治疗前两组患者头痛发作频率、头痛发作时间及头痛发作强度对比差异无统计学意义(P>0.05);经过3个月预防性治疗后,两组患者头痛发作频率、头痛发作时间及头痛发作强度均有明显改善(P<0.05);两组患者治疗后各指标对比差异无统计学意义(P>0.05)。两组患者治疗后的头痛指数较治疗前明显降低(P<0.05);两组患者治疗后头痛指数对比差异无统计学意义(P>0.05)。A组患者的不良反应发生率为3.03%,B组患者不良反应发生率为12.12%,A组患者不良反应发生率明显低于B组(P<0.05)。结论坎地沙坦和氟桂利嗪在预防性治疗偏头痛上均能起到较为明显的治疗效果,减轻头痛症状,而坎地沙坦的不良反应少,安全性高,值得在临床上推广应用。
Objective To explore the value of candesartan and flunarizine in the prevention of migraine. Methods 132 patients with migraine were randomly divided into A group and B group, 66 cases in each group. Candesartan was given to patients in group A, and to flunarizine in group B. The incidence of headache, headache index and incidence of adverse reactions in both groups were compared. Results There was no significant difference in headache attack frequency, headache attack time and intensity of headache between the two groups before treatment (P> 0.05). After three months of prophylaxis, headache frequency, headache and headache (P <0.05). There was no significant difference between the two groups after treatment (P> 0.05). After treatment, headache index of both groups was significantly lower than that before treatment (P <0.05). There was no significant difference in headache index between the two groups after treatment (P> 0.05). The incidence of adverse reactions in group A was 3.03%. The incidence of adverse reactions in group B was 12.12%. The incidence of adverse reactions in group A was significantly lower than that in group B (P <0.05). Conclusions Both candesartan and flunarizine can play a significant therapeutic effect in the preventive treatment of migraine, relieve headache symptoms, while candesartan has few adverse reactions and high safety, which is worth to be popularized clinically application.